RxDoctor Payments Data

Mouville Caro-Gracia, MD

Psychiatry · West Palm Beach, FLNPI 1003932229

Payments from drug & device makers

$68,526in general payments, 2019–2025

Across 543 payments — averaging $126.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$61K
  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$880
  • Alkermes, Inc.$767
  • plus $2K from 12 others

What the payments were for

  • Speaking & faculty fees$53,02577%
  • Travel & lodging$4,9017%
  • Food & beverage$10,38115%
  • Education$2200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,526 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$37,854
Medicare patients
99
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate134$447,911
AristadaAripiprazole Lauroxil104$331,442
IngrezzaValbenazine Tosylate24$250,234
Invega HafyeraPaliperidone Palmitate12$207,710
Austedo XrDeutetrabenazine22$207,001
Invega TrinzaPaliperidone Palmitate18$193,961
Abilify MaintenaAripiprazole61$168,949
LybalviOlanzapine/Samidorphan Malate63$102,476
NuedextaDextromethorphan Hbr/Quinidine17$20,524
Zyprexa RelprevvOlanzapine Pamoate16$18,818
VivitrolNaltrexone Microspheres11$18,656
Lurasidone Hcl39$9,851
Divalproex Sodium ErDivalproex Sodium84$9,690
TrintellixVortioxetine Hydrobromide15$9,546
Clozapine79$7,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$60,768$641,872152 claims
Alkermes, Inc.Aristada, Lybalvi, Vivitrol$767$452,574178 claims
Neurocrine Biosciences, Inc.Ingrezza$618$250,23424 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$1,003$207,00122 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$2,049$168,94961 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$9,54615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →